Microultrasound-targeted biopsy is comparable to multiparametric MRI-targeted biopsy for detecting prostate cancer, according to study results to be presented in this Wednesday morning session.
Canadian researchers included 94 men in an investigation that compared the two modalities' cancer detection performance. All of the men underwent initial microultrasound and multiparametric MRI exams for suspected prostate cancer, and if needed, an MRI (targeted) biopsy and a microultrasound (nontargeted) biopsy.
The two types of biopsies performed comparably across a variety of measures, including detection of clinically significant prostate cancer (p = 0.22), detection of insignificant disease (p > 0.99), and cribriform/intraductal prostate cancer (p = 0.99).
The combination of an MRI exam and microultrasound biopsy identified clinically significant prostate cancer in 40% of the men. The researchers also found that more men (34%) who had an initial MRI exam avoided biopsy completely compared to those who had an initial microultrasound (10%).
The two modalities are comparable when it comes to detecting prostate cancer, but MRI performs better when it comes to reducing biopsies.
"MRI and microultrasound showed similar cancer detection rates, but the MRI pathway avoided biopsy in more men than microultrasound," the team wrote.
Stop by this talk on Wednesday to learn more.
